Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China

• Váldodahkkit: Yi Zhang (Dahkki), Xiu-Jin Shi (Dahkki), Wen-Xing Peng (Dahkki), Jia-Lun Han (Dahkki), Bai-Di Lin (Dahkki), Ru Zhang (Dahkki), Yun-Nan Zhang (Dahkki), Jia-Lin Yan (Dahkki), Juan-Juan Wei (Dahkki), Yi-Fan Wang (Dahkki), Su-Wei Chen (Dahkki), Nan Nan (Dahkki), Zhen-Wei Fang (Dahkki), Yong Zeng (Dahkki), Yang Lin (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2021-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Background: CYP2C19 loss-of-function (LOF) alleles reduce the effectiveness of clopidogrel in patients undergoing percutaneous coronary intervention for acute coronary syndrome. However, the clinical impact of implementing CYP2C19 gene-guided pharmacotherapy is unclear, especially among the Chinese...